ABCB1 fusions have been proposed as a mechanism of upregulation and were found in approximately two-thirds of breast and ovarian cancer patients who had received three or more lines of paclitaxel and 26% of patients who received at least one line of liposomal doxorubicin [126]. This evidence concerns the gene ABCB1 and ovarian carcinoma.